Business context and reporting period
Filing identity: The supplied filing is Leap Therapeutics, Inc. (Nasdaq: LPTX), not Cypherpunk Technologies Inc. It is the Form 10-K for the fiscal year ended December 31, 2020, filed March 12, 2021; it reports annual results, not a standalone 2020 fourth quarter.
Leap is a clinical-stage biopharmaceutical company developing cancer therapies. Its lead candidate, DKN-01, targets DKK1 and was being studied in multiple cancer indications. No candidate had regulatory approval, and the company had generated no product-sales revenue. The company discontinued active development of TRX518 in November 2019, although it continued to report some TRX518-related R&D expense in 2020.
Financial performance and position
Amounts below are in U.S. dollars; millions unless stated otherwise.
| Metric | 2020 | 2019 |
|---|---|---|
| License revenue | $1.5 | None |
| Research and development expense | $20.4 | $24.4 |
| General and administrative expense | $9.6 | $9.1 |
| Operating loss | $28.5 | $33.5 |
| Net loss | $27.5 | $32.9 |
| Net loss attributable to common stockholders | $37.6 | $33.3 |
| Basic and diluted loss per share | $0.63 | $1.47 |
| Cash used in operating activities | $26.0 | $26.9 |
| Cash and cash equivalents at year-end | $52.1 | $3.9 |
The $1.5 million of license revenue was recognized from the $3.0 million upfront payment under the BeiGene agreement; $1.5 million remained deferred at year-end. No product sales or royalty revenue were reported. Profit margins are not meaningful for this pre-commercial, loss-making company.
At December 31, 2020, total assets were $54.4 million and total liabilities were $7.7 million, including $0.6 million of lease liabilities and $1.5 million of deferred revenue. The filing reports no off-balance-sheet arrangements and no material conventional debt balance. Current assets were $52.3 million versus current liabilities of $7.4 million. The company reported an accumulated deficit of $223.0 million.
Operating cash outflow was financed principally by $74.0 million of financing cash inflows, including approximately $48.5 million net proceeds from the June public offering and proceeds from the January preferred-stock financing. The company reported 59.7 million common shares outstanding at year-end, compared with 24.2 million a year earlier; substantial warrants and other equity awards also create potential dilution.
Changes versus 2019
- Net loss narrowed by $5.4 million, while operating loss narrowed by $4.9 million. R&D expense fell $3.9 million, mainly reflecting lower TRX518 and clinical-trial costs; DKN-01 program expense rose from $16.1 million to $18.0 million.
- G&A expense increased $0.5 million, as higher professional fees, payroll and insurance costs were partly offset by lower stock-based compensation.
- Cash increased by $48.2 million, largely due to equity financing. Operating cash use improved by about $0.9 million.
- Common-stockholder loss per share improved to $0.63 from $1.47, but the 2020 figure includes $10.1 million of preferred-stock dividends and beneficial-conversion-feature charges, as well as a $0.3 million warrant down-round dividend. Weighted-average shares increased substantially.
Outlook, commentary and risks
- Management believed year-end cash would fund operating expenses and capital requirements for at least 12 months from issuance of the financial statements. The company expected continuing operating losses and said additional financing or collaboration funding would likely be needed; absent funding, it might delay, reduce or eliminate trials or other programs.
- BeiGene received an option to develop and commercialize DKN-01 in Asia excluding Japan, Australia and New Zealand. Leap received $3.0 million upfront and could receive up to $132.0 million in future option-exercise and development, regulatory and sales milestones, plus tiered royalties. Future payments were uncertain, and BeiGene could terminate with notice. Initial data from the BeiGene-associated P205 study was expected in the second half of 2021.
- The FDA granted DKN-01 orphan drug designation for gastric and gastroesophageal junction cancer and Fast Track designation for a specified DKK1-high gastric/GEJ patient population. These designations do not constitute approval. DKN-01 remained investigational.
- Management described clinical findings in selected subgroups, including DKK1-high EGC patients receiving DKN-01 plus pembrolizumab and patients in a biliary-tract-cancer combination study. These were early clinical results, often from small, open-label or uncontrolled cohorts; management cautioned that later, larger controlled trials may produce different outcomes.
- Principal risks include clinical efficacy and safety uncertainty, regulatory approval and trial-enrollment delays, COVID-19 disruption, reliance on BeiGene and third-party manufacturers/CROs, competition, patent protection and the need for additional capital. The company relied on contract manufacturers and had no commercial sales infrastructure.
- Contractual commitments disclosed at year-end included $0.6 million for research/manufacturing and $0.6 million of operating-lease payments. Lilly and Lonza may receive low-single-digit royalties on future product sales; none had been paid or accrued through year-end.
Important facts for investors to verify
- Confirm the issuer: the filing text identifies Leap Therapeutics (LPTX), despite the request metadata naming a different company.
- Review the latest cash balance, operating cash burn and actual financing runway; the stated runway was a management estimate based on assumptions.
- Track DKN-01 trial progress and whether subgroup findings are confirmed in adequately powered, controlled studies, as well as regulatory milestones and timing.
- Check BeiGene’s option status, development activity, termination rights and any milestone or royalty receipts.
- Assess dilution from the substantial warrant overhang, equity awards and future financing needs; the filing lists 52.7 million warrants outstanding at year-end.
- Review the full audited financial statements and notes for financing terms, deferred license revenue, clinical commitments and the TRX518-related patent proceedings. The auditor issued an unqualified opinion on the financial statements; it did not provide an audit opinion on internal-control effectiveness.